| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Yibeissine acts on the central nervous system to alleviate pain. As a steroidal alkaloid, it may target specific receptors or ion channels involved in pain signaling. Further research is needed to identify and characterize its primary molecular targets. The compound has been used in traditional Chinese medicine for its analgesic and anti-inflammatory properties.
|
|---|---|
| ln Vitro |
Yibeissine demonstrates analgesic and anti-inflammatory properties. As a steroidal alkaloid, it may also exhibit other biological activities. Further studies are needed to fully characterize its in vitro pharmacological profile and to determine its potency against various targets. The compound acts on the central nervous system to alleviate pain.
|
| ln Vivo |
Specific in vivo activity data for Yibeissine are not extensively reported in the available literature. As a compound with analgesic and anti-inflammatory properties, it may exhibit efficacy in preclinical models of pain and inflammation. Further research is needed to characterize its pharmacokinetic and pharmacodynamic profiles in animal models.
|
| Enzyme Assay |
The in vitro assay for Yibeissine typically involves standard biochemical or cellular assays used for alkaloid compounds. These may include receptor binding studies, enzyme inhibition assays, or cell-based assays for analgesic or anti-inflammatory activity. The compound is tested at various concentrations, and the biological activity is quantified using appropriate readouts such as IC50 or EC50 values.
|
| Cell Assay |
The in vitro cellular assay for Yibeissine typically involves culturing relevant cell lines (e.g., neuronal cells, immune cells) in appropriate growth media. Cells are treated with varying concentrations of the compound, and cellular responses such as calcium influx, cytokine secretion, or cell viability are measured using standard assays.
|
| Animal Protocol |
In vivo animal studies for Yibeissine would typically involve the use of rodent models of pain or inflammation. Animals would be administered the compound via appropriate routes (e.g., oral gavage, intraperitoneal injection, or subcutaneous injection). Pain responses would be assessed using standard pain tests such as the tail-flick test, hot plate test, or formalin test. Inflammatory markers would be measured in blood or tissues.
|
| ADME/Pharmacokinetics |
Yibeissine has a molecular weight of 443.62 g/mol and a molecular formula of C27H41NO4. The compound should be stored as a powder at -20°C for up to 3 years. It has a purity of ≥98%. The compound is soluble in organic solvents. Further detailed physicochemical properties are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Yibeissine are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References | |
| Additional Infomation |
Yibeissine is a steroidal alkaloid isolated from the bulb of Fritillaria pallioiflora Schren. It has been used in traditional Chinese medicine for its analgesic and anti-inflammatory properties. The compound acts on the central nervous system to alleviate pain. It is also known by its CAS number 143502-51-6. It has not yet entered clinical trials and is strictly for preclinical research purposes.
|
| Molecular Formula |
C27H41NO4
|
|---|---|
| Molecular Weight |
443.618748426437
|
| Exact Mass |
443.304
|
| CAS # |
143502-51-6
|
| PubChem CID |
3083381
|
| Appearance |
White to off-white solid powder
|
| Density |
1.22g/cm3
|
| Boiling Point |
611.6ºC at 760mmHg
|
| Flash Point |
323.7ºC
|
| Vapour Pressure |
1.64E-17mmHg at 25°C
|
| Index of Refraction |
1.59
|
| LogP |
3.56
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
32
|
| Complexity |
855
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@H]1C[C@@H]2[C@H]([C@H]([C@]3(O2)CC[C@H]4[C@@H]5CC(=O)[C@H]6C[C@H](CC[C@@]6([C@H]5[C@H](C4=C3C)O)C)O)C)NC1
|
| InChi Key |
NURPXYQPDMVKOY-RUKZUWONSA-N
|
| InChi Code |
InChI=1S/C27H41NO4/c1-13-9-21-24(28-12-13)15(3)27(32-21)8-6-17-18-11-20(30)19-10-16(29)5-7-26(19,4)23(18)25(31)22(17)14(27)2/h13,15-19,21,23-25,28-29,31H,5-12H2,1-4H3/t13-,15+,16-,17-,18-,19+,21+,23+,24-,25-,26-,27-/m0/s1
|
| Chemical Name |
(3S,3'R,3'aS,4aS,6'S,6aS,6bS,7'aR,9R,11R,11aS,11bR)-3,11-dihydroxy-3',6',10,11b-tetramethylspiro[1,2,3,4,4a,6,6a,6b,7,8,11,11a-dodecahydrobenzo[a]fluorene-9,2'-3a,4,5,6,7,7a-hexahydro-3H-furo[3,2-b]pyridine]-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2542 mL | 11.2709 mL | 22.5418 mL | |
| 5 mM | 0.4508 mL | 2.2542 mL | 4.5084 mL | |
| 10 mM | 0.2254 mL | 1.1271 mL | 2.2542 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
